Longevity Startups: Why Billionaires Are Investing in Extending Human Life

Imagine building a technology empire, becoming a billionaire in your thirties, and then discovering the one thing your fortune cannot buy: more time. Success has trained you to believe almost anything is solvable. So when mortality finally becomes personal, the instinct is not acceptance - it is engineering. The question shifts from “How do I live longer?” to something colder and more ambitious: “What if ageing itself is just another system that can be reverse-engineered, funded, and defeated?”

The desire to extend human life is ancient. What is different today is the combination of scientific advances, extraordinary technology wealth and the scale of capital being committed to the pursuit. Some of the world's wealthiest entrepreneurs are now backing ventures that seek to understand ageing, rejuvenate cells and extend the years people live in good health.

To understand why longevity has become a serious technology and investment pursuit, it helps to trace the journey from ancient myths of immortality to the modern laboratories and startups attempting to change the biology of ageing.

The Quest for Immortality: From Hindu Mythology to Modern Longevity Research

Stage 1 — Mythology: the desire to escape death

In Hindu mythology, the quest for immortality appears in several powerful forms. In the Samudra Manthan, the churning of the cosmic ocean produces Amrita, the nectar associated with immortality, sought by the Devas. The story captures a deeply rooted idea: that death might be overcome through access to something extraordinary.

Other traditions reinforce this theme. Markandeya is associated with overcoming death through divine grace, while the Chiranjivi tradition describes beings who continue to live across ages. These are religious and mythological narratives, not historical claims of biological immortality. Yet they reveal how long the human desire to transcend mortality has endured.

Stage 2 — The Middle Ages: the search for an elixir

The quest moved beyond stories into attempts to discover practical methods of extending life. Alchemists pursued elixirs of life and the philosopher's stone, while medical and spiritual traditions developed their own approaches to vitality and longevity.

In India, Rasayana, a branch of Ayurveda concerned with rejuvenation and longevity, formed part of a wider tradition of seeking to preserve health and vitality. These approaches differed considerably across cultures, and none established a reliable means of achieving immortality.

The ambition, however, remained: perhaps the right substance, knowledge or method could delay the inevitable.

Stage 3 — 2013–2019: longevity becomes a technology-backed pursuit

Modern biology began offering ways to investigate ageing as a biological process rather than an immutable mystery. Research into genomics, stem cells, cellular senescence and age-related disease opened new avenues for scientific investigation.

Google's launch of Calico in 2013 was a prominent milestone in the entry of major technology companies into this field. Other ventures pursued specific biological mechanisms and potential therapies. The goal was increasingly to understand ageing scientifically and develop interventions that might extend healthy life.

Stage 4 — 2019 onwards: extraordinary technology wealth meets the longevity quest

The rapid creation of technology wealth, particularly around the pandemic-era boom, coincided with a new wave of exceptionally well-funded longevity research. Retro Biosciences emerged in 2021 with Sam Altman's backing, and Altos Labs launched in 2022 with $3 billion in committed funding.

In India, Deepinder Goyal committed $25 million to Continue Research in 2025. These examples illustrate how substantial personal fortunes can finance ambitious scientific programmes with uncertain outcomes and long time horizons.

The latest stage is distinguished by the scale of resources being committed to this age-old ambition. Some of the world's wealthiest technology entrepreneurs are now financing research into the biological processes that govern ageing, with the hope of extending healthy human life. The following ventures illustrate how this ambition is translating into research programmes, scientific approaches and substantial financial commitments.

Longevity is not the only frontier attracting extraordinary capital. My earlier perspective, Is AI a Bubble? Investment, Returns and Lessons from History, explores a related question: how do we distinguish transformative scientific potential from investment expectations?

Five Longevity Startups to Know, Including Deepinder Goyal’s Continue Research

1. Altos Labs

Founded: 2022

Key investors: Jeff Bezos, Yuri Milner and other investors

Website: https://www.altoslabs.com/

Altos Labs focuses on cellular rejuvenation and the study of how cells can be restored to healthier, more resilient states. Launched with $3 billion in committed funding, it is among the most heavily funded ventures in the longevity sector.

2. Retro Biosciences

Founded: 2021

Key backer: Sam Altman

Website: https://www.retro.bio/

Retro Biosciences aims to extend healthy human lifespan by developing therapies targeting the biological mechanisms of ageing. Its research includes autophagy, stem-cell therapies and cellular reprogramming. Sam Altman initially committed $180 million of personal capital to the venture.

3. NewLimit

Founded: 2021

Co-founders: Brian Armstrong and Blake Byers

Website: https://www.newlimit.com/

NewLimit is developing medicines intended to restore youthful function in ageing cells through epigenetic reprogramming. The company combines biotechnology research with computational and AI-assisted approaches to identify potential therapies for age-related conditions.

4. Calico

Founded: 2013

Parent company: Alphabet (Google)

Website: https://www.calicolabs.com/

Calico was an early, prominent example of a major technology company entering longevity research. Its work focuses on understanding the biology of ageing and developing interventions for age-related diseases. Its establishment marked an important milestone in bringing Silicon Valley's resources and long-term research ambitions to the field.

5. Continue Research

Founded by: Deepinder Goyal, co-founder of Zomato

Announced funding: $25 million in personal capital, 2025

Website: https://www.continue.com/

Continue Research is an Indian entrepreneur-led research initiative and seed fund focused on extending healthy human life. Goyal committed $25 million of personal capital to support research into ageing and human biology. His involvement brings the longevity movement into the Indian entrepreneurial context, connecting the wealth created through a successful technology business with an ambition to investigate the limits of human life.

Funding and ambition tell us how seriously investors are pursuing longevity, but the scientific work itself tells us what may be possible. While no intervention has yet been proven to reverse human ageing or substantially extend maximum human lifespan, several areas have made meaningful scientific progress. To understand where this quest stands today, it is worth looking at five areas in which research has advanced our understanding of ageing and begun to explore potential interventions.

Five Notable Advances in Longevity Research

1. Understanding the biology of ageing: Researchers have identified biological processes associated with ageing, including cellular senescence, DNA damage and changes in gene regulation. This has helped shift research from treating individual diseases towards investigating mechanisms that contribute to multiple age-related conditions.

2. Senolytics — targeting ageing cells: Scientists are investigating drugs that selectively remove senescent cells, which can contribute to inflammation and tissue dysfunction. Human trials have begun, but results have been mixed. A 2025 US National Institute on Aging-funded trial found only limited benefits for bone health in older women.

3. Cellular reprogramming: Research has shown that altering cellular reprogramming pathways can restore some youthful characteristics in cells and animal models. In October 2026, Life Biosciences reported preliminary results from an early human trial of an experimental treatment for optic nerve conditions. This is an important step towards human testing, not proof of rejuvenation throughout the body.

4. Rapamycin and related drugs: These drugs affect mTOR, a pathway involved in cellular growth and ageing. A 2024 systematic review found improvements in certain physiological measures, but evidence was limited across several body systems. Human lifespan extension has not been demonstrated.

5. The growing ability to measure biological ageing: Researchers are developing molecular biomarkers and biological-age estimates to assess aspects of ageing beyond chronological age. These tools could help researchers evaluate interventions more efficiently, although a change in a biological-age measurement does not necessarily mean a person will live longer.

The Future of Longevity: Can We Really Extend Human Life?

It is too early to know whether these ventures will fundamentally change the human lifespan, and the gap between promising laboratory results and proven therapies in humans remains substantial.

Reversing ageing or dramatically extending life may prove far more difficult than even their founders anticipate. Yet research is expanding our understanding of the biological processes that drive ageing and opening new avenues for treating age-related diseases. Some approaches may fail, others may take decades to mature, and a few may produce breakthroughs that are difficult to foresee today. Even if humanity does not conquer mortality, the effort could help us live healthier for longer. And that alone may be a worthwhile outcome.